The H6PD Knockout SK-OV-3 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of the human ovarian adenocarcinoma SK-OV-3 cell line, designed for investigating hexose-6-phosphate dehydrogenase (H6PD) function. This polyclonal pool offers a heterogeneous loss-of-function model, avoiding clonal selection bias.
SK-OV-3 cells, originally derived from ascites of a 64-year-old female with ovarian adenocarcinoma, are characterized by a metastatic and drug-resistant phenotype, making them a widely employed model for studying oncogenic pathways, metabolic reprogramming, and therapeutic resistance in ovarian cancer.
H6PD is an ER enzyme that converts glucose-6-phosphate to 6-phosphogluconolactone using NADP+, generating NADPH essential for HSD11B1-mediated cortisone-to-cortisol activation, glutathione reduction, and NADPH-dependent lipid synthesis. Its expression is controlled by NRF2, ATF4, ER stress sensors (IRE1, PERK), and glucose availability. H6PD interacts with HSD11B1 and ER oxidoreductases, coupling metabolic signals to glucocorticoid activation and ER redox homeostasis.
Ovarian cancer cells rely on enhanced NADPH supply for biosynthesis and antioxidant defense. Knocking out H6PD in SK-OV-3 cells depletes ER NADPH, impairing cortisol production and increasing sensitivity to oxidative stress, thus revealing metabolic dependencies relevant to drug resistance and tumor progression.
Applications include NADPH quantification, HSD11B1 activity measurement, cell viability and colony formation under oxidative stress, drug sensitivity profiling, migration assays, and metabolomic analyses such as LC-MS glucocorticoid quantification. The polyclonal design supports pooled functional screens and pathway interrogation. For further assistance, contact Ascent Research.
